BioSpace News Archive

Amwell ® , a national telehealth leader, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC

Kaiser Permanente announced that Catherine Hernandez has been named senior vice president and chief communications officer of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals.

Rafael Holdings, Inc., (NYSE: RFL), today announced that it will present at The LD 500 Virtual Conference on Thursday, September 3, 2020 . David Polinsky , Rafael’s Chief Financial Officer, will dis

Aimmune Therapeutics, Inc. announced that findings from APPEAL-2, the largest cross-sectional, pan-European, qualitative study to evaluate the psychosocial burden of living with peanut allergy, were published in Clinical & Experimental Allergy, the official journal of the British Society for Allergy & Clinical Immunology.

Lumiata announced FGC Health, based out of Winnipeg, Manitoba, Canada, has signed a contract to use Lumiata’s artificial intelligence predictive models to identify high-risk patients.

PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that Dr. David Stein has been appointed as its new Chairman of the Board. Dr. Stein, along with members of the PixCell Medical Board of Directors,

PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce its intention to proceed with a share consolidation (the “Consolidation”) of its issued and outstanding common shares (“Common Shares”) on the basis of one (1) post-consolidation Common Share for every fifteen (15) pre-consolidation Common Shares.

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate

Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.